Figure 1.

Allicin treatment improves reticuloendotheliosis virus (REV)-induced inhibition of growth and immune function. (A) The body weight loss observed in the REV group was improved by 300 mg/kg allicin treatment (Week 2: n = 40/group; Week 3: n = 32/group; Week 4: n = 24/group; Week 5: n = 16/group; and Weeks 6, 7, and 9: n = 8). (B) The index of thymuses (n = 8). (C) The index of spleens (n = 8). (D) The index of the bursa of Fabricius (n = 8). (E) The viability of REV-infected cells (n = 6). (F) The effect of allicin on the viability of 20 TCID₅₀ REV-infected cells (n = 6). The values are expressed as mean ± SE.